JPMorgan: Hansoh Pharmaceutical (03692.HK)'s collaboration with Roche confirms the company's capabilities; target price HK$50

Zhitong Finance APP has learned that JPMorgan released a research report stating that Hansoh Pharmaceutical (03692.HK) announced the signing of a multi-project antibody-drug conjugate (ADC) collaboration agreement with Roche, covering two of Hansoh's preclinical ADCs as well as multiple ADC projects targeting targets proposed by Roche; the bank maintains an "Overweight" rating on Hansoh Pharmaceutical with a target price of HK$50, and expects a positive share price reaction with single-digit percentage upside.